

Gianluca Sala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4547564/publications.pdf>

Version: 2024-02-01

66
papers

1,915
citations

257450

24
h-index

265206

42
g-index

69
all docs

69
docs citations

69
times ranked

2819
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Phosphoinositide 3-Kinase C2 β in Insulin Signaling. <i>Journal of Biological Chemistry</i> , 2007, 282, 28226-28236.	3.4	136
2	Phospholipase C β 1 Is Required for Metastasis Development and Progression. <i>Cancer Research</i> , 2008, 68, 10187-10196.	0.9	135
3	The G α protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1. <i>FASEB Journal</i> , 2000, 14, 2569-2580.	0.5	131
4	Feedback inhibition by RALT controls signal output by the ErbB network. <i>Oncogene</i> , 2003, 22, 4221-4234.	5.9	112
5	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. <i>Oncogene</i> , 2005, 24, 4540-4548.	5.9	111
6	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5510.	4.1	83
7	BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. <i>Nature Communications</i> , 2015, 6, 8695.	12.8	81
8	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. <i>Oncogene</i> , 2018, 37, 6368-6382.	5.9	77
9	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. <i>Cell Death and Disease</i> , 2015, 6, e1823-e1823.	6.3	74
10	Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. <i>Oncogene</i> , 2002, 21, 6530-6539.	5.9	73
11	Functional and prognostic significance of the genomic amplification of frizzled 6 (<i>FZD6</i>) in breast cancer. <i>Journal of Pathology</i> , 2017, 241, 350-361.	4.5	66
12	Role of BAG3 in cancer progression: A therapeutic opportunity. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 85-92.	5.0	61
13	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. <i>Oncotarget</i> , 2015, 6, 3932-3946.	1.8	60
14	Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. <i>Journal of Translational Medicine</i> , 2021, 19, 405.	4.4	50
15	A Phosphoinositide 3-Kinase/Phospholipase C γ 1 Pathway Regulates Fibroblast Growth Factor-Induced Capillary Tube Formation. <i>PLoS ONE</i> , 2009, 4, e8285.	2.5	37
16	Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8 ⁺ T cell number and tumour growth in pancreatic cancer. <i>Gut</i> , 2018, 67, gutjnl-2017-314225.	12.1	33
17	Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1555.	4.1	33
18	Negative regulation of receptor tyrosine kinase signals. <i>FEBS Letters</i> , 2001, 490, 132-141.	2.8	32

#	ARTICLE	IF	CITATIONS
19	miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES1 induction. <i>FASEB Journal</i> , 2019, 33, 6933-6947.	0.5	30
20	Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates. <i>Journal of Controlled Release</i> , 2019, 294, 176-184.	9.9	30
21	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. <i>EMBO Molecular Medicine</i> , 2020, 12, e11498.	6.9	30
22	ErbB-3 activation by NRG-1 β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). <i>Oncotarget</i> , 2015, 6, 16902-16911.	1.8	29
23	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. <i>Oncogene</i> , 2012, 31, 1275-1286.	5.9	28
24	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. <i>Translational Oncology</i> , 2013, 6, 676-IN9.	3.7	26
25	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. <i>Journal of Controlled Release</i> , 2018, 277, 48-56.	9.9	23
26	Breast cancer in the era of integrating "Omics" approaches. <i>Oncogenesis</i> , 2022, 11, 17.	4.9	23
27	EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. <i>Oncotarget</i> , 2017, 8, 95412-95424.	1.8	22
28	PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. <i>BMC Cancer</i> , 2019, 19, 747.	2.6	22
29	Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 312.	8.6	18
30	ABCC3 is a novel target for the treatment of pancreatic cancer. <i>Advances in Biological Regulation</i> , 2019, 73, 100634.	2.3	18
31	Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer. <i>Molecular Oncology</i> , 2019, 13, 1388-1399.	4.6	18
32	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. <i>Cancers</i> , 2020, 12, 2989.	3.7	16
33	Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 191.	8.6	14
34	The E27 β 2-adrenergic Receptor Polymorphism Reduces the Risk of Myocardial Infarction in Dyslipidemic Young Males. <i>Thrombosis and Haemostasis</i> , 2001, 85, 231-233.	3.4	13
35	Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. <i>Oncogenesis</i> , 2014, 3, e117-e117.	4.9	13
36	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. <i>Oncotarget</i> , 2017, 8, 60368-60377.	1.8	13

#	ARTICLE	IF	CITATIONS
37	High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 63.	8.6	13
38	USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer. <i>Oncogenesis</i> , 2021, 10, 28.	4.9	13
39	Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy. <i>Pharmaceutics</i> , 2020, 12, 992.	4.5	12
40	Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 3126.	3.7	12
41	The role of phospholipase C β 1 in breast cancer and its clinical significance. <i>Future Oncology</i> , 2017, 13, 1991-1997.	2.4	11
42	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. <i>Cell Death and Disease</i> , 2022, 13, 274.	6.3	11
43	CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs Letter. <i>Clinical Cancer Research</i> , 2019, 25, 892-893.	7.0	10
44	p63 role in breast cancer. <i>Aging</i> , 2016, 8, 2256-2257.	3.1	10
45	Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. <i>Gut</i> , 2023, 72, 360-371.	12.1	8
46	EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. <i>Pharmaceutics</i> , 2021, 13, 483.	4.5	7
47	BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 65-76.	2.6	6
48	The E27 beta2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males. <i>Thrombosis and Haemostasis</i> , 2001, 85, 231-3.	3.4	6
49	Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. <i>Oncogenesis</i> , 2020, 9, 3.	4.9	5
50	MYC regulates metabolism through vesicular transfer of glycolytic kinases. <i>Open Biology</i> , 2021, 11, 210276.	3.6	5
51	Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. <i>Cancers</i> , 2019, 11, 1695.	3.7	4
52	HER-3: hub for escape mechanisms. <i>Aging</i> , 2015, 7, 899-900.	3.1	4
53	EV20-ssvc/MMAF, an HER3 targeting antibody-drug conjugate displays antitumor activity in liver cancer. <i>Oncology Reports</i> , 2020, 45, 776-785.	2.6	3
54	Concerted BAG3 and SIRP β blockade impairs pancreatic tumor growth. <i>Cell Death Discovery</i> , 2022, 8, 94.	4.7	2

#	ARTICLE	IF	CITATIONS
55	Abstract 748: Non-internalizing site-specific antibody-drug conjugates based on maytansinoids display curative properties. , 2018, , .		1
56	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		1
57	1226 POSTER An ErbB-3 Antibody, MP-RM-1, Inhibits Tumour Growth by Blocking Ligand-dependent and Independent Activation of ErbB-3/Akt Signaling. European Journal of Cancer, 2011, 47, S152.	2.8	0
58	505 The anti-ErbB3 antibody, EV20, counteracts vemurafenib resistance in BRAF-mutated colorectal cancer stem cells. European Journal of Cancer, 2014, 50, 164-165.	2.8	0
59	Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling.. Journal of Clinical Oncology, 2011, 29, e13538-e13538.	1.6	0
60	Abstract C58: Humanization and characterization of an anti-ErbB-3 murine monoclonal antibody.. , 2011, , .		0
61	Abstract 5437: Dual targeting of ErbB-2 and ErbB-3: A new potential strategy for the treatment of pancreatic cancer. , 2014, , .		0
62	Abstract LB-A14: Targeting BAG3-dependent paracrine loop reduces growth and metastatic spreading of Pancreatic adenocarcinoma. , 2015, , .		0
63	Abstract 40: Development of a novel antibody-drug conjugate targeting endosialin/TEM-1: potent antitumor activity in sarcoma. , 2017, , .		0
64	Abstract 41: An Antibody Drug Conjugate targeting HER-3 demonstrates promising antitumor efficacy in a wide range of human cancer. , 2017, , .		0
65	Abstract 741: Targeting trastuzumab and T-DM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3. , 2018, , .		0
66	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		0